Gracell Biotechnologies Inc.

NasdaqGS:GRCL Stock Report

Market Cap: US$990.8m

Gracell Biotechnologies Future Growth

Future criteria checks 0/6

Gracell Biotechnologies's earnings are forecast to decline at 5.5% per annum while its annual revenue is expected to grow at 65.1% per year. EPS is expected to grow by 19.8% per annum. Return on equity is forecast to be -31.7% in 3 years.

Key information

-5.5%

Earnings growth rate

19.8%

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate65.1%
Future return on equity-31.7%
Analyst coverage

Good

Last updated10 Feb 2024

Recent future growth updates

Recent updates

AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)

Feb 21

Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform

Sep 22

Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02

Aug 15

Gracell Biotechnologies rallies after naming new chief medical officer

Aug 01

Gracell names Dr. Samuel Zhang as Chief Business Officer

Jul 19

Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment

Nov 26

Gracell ends IPO quiet period with favorable views from analysts

Feb 02

Earnings and Revenue Growth Forecasts

NasdaqGS:GRCL - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202690-813-689N/A4
12/31/2025N/A-706-654N/A7
12/31/2024N/A-603-601N/A8
12/31/2023N/A-491-607N/A8
9/30/2023N/A-497N/AN/AN/A
6/30/2023N/A-601-594-560N/A
3/31/2023N/A-601N/AN/AN/A
12/31/2022N/A-608-531-483N/A
9/30/2022N/A-605N/AN/AN/A
6/30/20220-563-438-381N/A
3/31/20220-513N/AN/AN/A
12/31/20210-454-361-305N/A
9/30/20210-425N/AN/AN/A
6/30/2021N/A-365N/AN/AN/A
3/31/2021N/A-332N/AN/AN/A
12/31/2020N/A-275-278-198N/A
9/30/2020N/A-228-243-167N/A
12/31/2019N/A-201-192-135N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GRCL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GRCL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GRCL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GRCL is forecast to have no revenue next year.

High Growth Revenue: GRCL is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GRCL is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/21 06:34
End of Day Share Price 2024/02/21 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gracell Biotechnologies Inc. is covered by 8 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin ZelinBTIG
Louise ChenCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc